Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

This study has been completed.
Sponsor:
Information provided by:
West Penn Allegheny Health System
ClinicalTrials.gov Identifier:
NCT00548912
First received: October 23, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
  Purpose

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass


Condition Intervention Phase
Kidney Failure, Chronic
Drug: Spironolactone
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by West Penn Allegheny Health System:

Primary Outcome Measures:
  • Left ventricular mass [ Time Frame: 9 months ]

Detailed Description:

Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • hemodialysis patients

Exclusion Criteria:

  • non compliance
  • hyperkalemia
  • pregnancy
  • expected survival less than 9 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00548912

Locations
United States, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
Sponsors and Collaborators
West Penn Allegheny Health System
Investigators
Principal Investigator: Richard Marcus West Penn Allegheny Health System
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00548912     History of Changes
Other Study ID Numbers: RC-3267
Study First Received: October 23, 2007
Last Updated: October 23, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by West Penn Allegheny Health System:
Kidney Failure, Chronic
Hemodialysis
Spironolactone

Additional relevant MeSH terms:
Hypertrophy, Left Ventricular
Kidney Failure, Chronic
Renal Insufficiency
Cardiomegaly
Cardiovascular Diseases
Heart Diseases
Hypertrophy
Kidney Diseases
Pathological Conditions, Anatomical
Renal Insufficiency, Chronic
Urologic Diseases
Spironolactone
Cardiovascular Agents
Diuretics
Diuretics, Potassium Sparing
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Mineralocorticoid Receptor Antagonists
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014